The Cancer Letter

Inside information on cancer research and drug development

Funding Opportunities

SITC opens calls for nominations for 2022 Steven A. Rosenberg Scholars Award

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The Society for Immunotherapy of Cancer opened calls for nominations for the Steven A. Rosenberg Scholars Award May 1. This award provides $150,000 in funding to advance the research of an early career scientist in the field of immunology and cancer immunotherapy. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Weill Cancer Hub East to investigate connections between metabolism and anti-tumor immunity
Weill Cornell, Rockefeller, Princeton and the Ludwig Institute for Cancer Research showcase the power of collaboration

The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 
By Jedd D. Wolchok, Joshua D. Rabinowitz and Sohail Tavazoie
In Brief

Beverly Ginsburg Cooper honored with ACCA Career Achievement award

The Association of Corporate Career Advancement presented its inaugural ACCA Career Achievement Award to Beverly Ginsburg Cooper, managing director at the Huron Consulting Group, on March 16. Given at the CCA Annual Business Meeting in Seattle, the ACCA Career Achievement Award recognizes current members of the Association of Cancer Center Administrators or former members of the Cancer Centers Administrators Forum who have demonstrated exemplary dedication, leadership, and lasting contributions to the field of cancer administration.
Clinical Roundup

Investigational Orca-T treatment for hematologic malignancies meets primary endpoint in phase III trial

Orca Bio, a late-stage biotechnology company, on March 17 announced results from the pivotal phase III Precision-T study of Orca-T, its lead investigational allogeneic T-cell immunotherapy, in patients with acute myeloid leukemia, acute lymphoblastic leukemia, high-risk myelodysplastic syndrome and mixed-phenotype acute leukemia. Orca-T is manufactured using highly purified regulatory T-cells, hematopoietic stem cells and conventional T-cells derived from peripheral blood from either related or unrelated matched donors.
Clinical Roundup

Chemo-immunotherapy approach shows potential benefit in advanced HPV-negative head-and-neck cancer

Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus-negative head-and-neck squamous cell carcinoma. More than half of study participants had 50% or more of their tumors shrink after receiving the immunotherapy drug nivolumab with chemotherapy, followed by response-adaptive chemo-radiation therapy. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account